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Abstract
Background: Comprehensive epidemiological data to describe the burden of heart failure (HF) in Australia remain
lacking despite its importance as a major health issue. Herewith, we estimate the current and future burden of HF
in Australia using best available data.
Methods: Australian-specific and the most congruent international epidemiological and health utilisation data were
applied to the Australian population (adults aged ≥ 45 years, 8.9 of 22.7 million total population in 2014) on an age
and sex-specific basis. We estimated the current incident and prevalent cases of clinically overt/symptomatic HF
(predominately those with reduced ejection fraction), hospital activity (diagnosis of HF as a primary or secondary
reason for admission) and health care costs in 2014 and future prevalence and burden of HF projected to 2030.
Results: We estimated that over 61,000 (6.9 per 1000 person-years) adult Australians aged ≥ 45 years (58 % women)
are diagnosed with HF with clinically overt signs and symptoms every year. On a conservative basis, 480,000 (6.3 %,
95 % CI 2.6 to 10.0 %) Australians (66 % men) are now affected by the syndrome with > 150,000 hospitalisations in
excess of 1 million days in hospital per annum. The annual cost of managing HF in the community is approximately
$900 million and nearly $2.7 billion ($1.5 versus $1.2 billion, men versus women) when considering the additional
cost of in-patient care. We predict that the prevalence and future burden of HF will continue to increase over the
next 10–15 years to nearly 750,000 people with an estimated annual health care cost of $3.8 billion.
Conclusions: Australia is not immune to the growing magnitude and implications of a sustained epidemic of HF in
an ageing population. However, its public health and economic burden will remain ill-defined until more definitive
Australian-specific data are generated.
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Background
Heart failure (HF) is one of the most prevalent cardio-
vascular diseases worldwide and is routinely attributed
to be the leading cause of hospitalisation in persons
aged ≥ 65 years [1]. Despite a relative paucity of specific
information (from its epidemiology to health care epi-
sodes), Australia is not immune to this significant public
health issue. More than a decade ago, we estimated that
approximately 325,000 adult Australians (4.5 % of those
aged ≥ 45 years) were directly affected by this complex
syndrome with around 100,000 hospital admissions per
annum attributable to HF overall [2]. Ominously, for the
Australian health care system, we also identified around
214,000 Australians with asymptomatic left ventricular
systolic dysfunction at that time and have tracked re-
sidually high levels of antecedent risk for developing the
syndrome; particularly relating to remnant high blood
pressure levels in the community [3] and suboptimal
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levels of hypertension management in primary care [4].
At the same time, the Australian population has not only
expanded but progressively aged since our last HF burden
estimates. The latter becomes an increasingly important
factor when considering the scope of HF has evolved with
increasing awareness and recognition of HF associated
with preserved ejection fraction (HFpEF - particularly
among older women with a history of hypertension) [5].
This clinical entity remains problematic both in terms of
diagnosis and treatment [6, 7]. In this context, HF with
reduced ejection fraction (HFrEF) [6] remains a major
clinical and public health focus with the efforts to improve
its detection and treatment continuously evolving.
Importantly, since our last set of estimates (largely reli-
ant on international data), a number of recent Australian-
specific studies relating to the population prevalence of
HF (notably the Canberra Heart Study [8]) and HF-related
hospital activity (the West Australian linked data re-
source [9]) have provided a greater certainty around the
epidemiological profiling of the syndrome when extrap-
olated to the latest and projected population figures for
the whole of Australia [10, 11]. For the purpose of this
study, we largely focused on incident and prevalent cases
of HFrEF with or without a component of diastolic dys-
function (the hallmark of HFpEF) within the Australian
population whilst providing some estimates of the likely
burden imposed by HFpEF alone.
Study aims
Based on the changing population dynamics and more
Australian-specific data, we aimed to produce a more ac-
curate set of figures (from its population profile to hospital
and community care activity) to describe various aspects of
the contemporary burden of HF (as noted, predominantly
that associated with systolic dysfunction as evidenced by
reduced left ventricular ejection fraction) in Australia.
Methods
All data sources had appropriate ethics approval and this
study was conducted according to the principles outlined
in the Declaration of Helsinki [12].
Investigational strategy and data sources
To conservatively estimate the current incident and preva-
lent cases of HFrEF in the Australian adult population
(aged ≥ 45 years), we evaluated a combination of validated
Australian-specific and international peer-reviewed epi-
demiological and clinical trial datasets (see Table 1). These
were applied to the latest Australian Bureau of Statis-
tics population figures according to geographic locale
on an age and sex-specific basis [10]. Based on our pre-
viously published reports [2, 13], this represents a vali-
dated method for estimating the burden of HF in Australia
[2] and beyond [13]. Consistent with this approach, the
following were applied when selecting data to shape
our burden estimates: 1) original Australian data (via a
systematic review of the literature and in consultation
with a panel of Australian HF clinical research aca-
demics/experts) were utilised [8, 9] in preference to
overseas data; 2) preference was given to the most com-
prehensive and contemporary datasets or according to
the purpose it was best suited, this included use of Western
Australia linked data [9] to estimate new/de novo HF-
related admissions as opposed to the broader New South
Wales data [14] describing all primary and secondary
admissions for HF per annum; and 3) where there were
no contemporary Australian-specific data available, the
most congruent international data were identified and
utilised [15–17].
Population profile
We obtained the Australian Bureau of Statistics Australian
population data on an age and sex-specific basis and ac-
cording to geographic locale as at June 2014 [10]. Data for
all persons aged ≥ 45 years (8,864,528) were grouped into
10-year age brackets except for those aged ≥ 75 years,
who were treated as a single group. This was under-
taken for both men and women and for each Australian
State and Territory.
Incident and prevalent cases
Incident cases were defined as the annual number of
new/de novo cases of HF predominantly associated with
HFrEF (where individuals must present with appropri-
ate symptoms and anomalies in the underlying cardiac
structure and function associated with systolic dysfunc-
tion as evidenced by reduced left ventricular ejection
fraction) and calculated by applying annual age and
sex-specific incidence rates derived from international
incidence statistics [15, 16] to the Australian Bureau of
Statistics 2014 Australian population by 10-year age groups.
Similarly, prevalent cases were defined as the combined
total of new/de novo and surviving/pre-existing cases of
HFrEF and calculated based on an annual point preva-
lence basis using a combination of Australian [8] and
international [16, 17] prevalence data.
Hospital activity
A broad range of parameters pertaining to HF-related
hospitalisations (confirmed by the International Classi-
fication of Diseases 9th edition [ICD-9] and 10th edition
[ICD-10] diagnostic codes for HF) were derived from
Australian-specific data alone [9]. This includes estimates
of: 1) incident hospital admissions associated with a pri-
mary (ICD-9 codes: 428x, 402.01, 402.11, 402.91, 404.1,
404.3, 425x, 518.4, 514, 391.8, and 398.91, and ICD-10
codes: I50x, I11.0, I13.0, I13.2, I42x, J81, I01.8, I02.0) or
secondary (with a principal diagnosis of a cardiovascular
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condition such as ischemic heart disease or atrial fibrilla-
tion, but not acute myocardial infarction) diagnosis of com-
posite HF, 2) type of admission (unplanned or planned),
3) length of hospital stay (LOS), 4) in-patient case-fatality,
5) discharge destinations (i.e. own home, acute hospital or
long-term rehabilitation or residential/supported care),
6) readmissions within 12 months and 7) any hospital
admissions (new/de novo or recurrent event) associated
with a primary or secondary diagnosis of HF overall
and LOS per annum.
Health care costs
Estimations of the annual cost of managing those indi-
viduals hospitalised with HF including the cost of their
in-patient care (including per diem hospital costs) and
auxiliary device therapy plus associated community man-
agement costs were based on a recently published HF-
specific management trial detailing all health care costs
typically associated with the management/care of pa-
tients presented with a composite diagnosis of HF within
Australia [18]. These were applied to prevalent cases of
HF (but not additional cases of HFpEF alone). Specifically,
community management costs including allied health
professionals and health services respective unit cost
($1825 per year) was multiplied by all HFrEF cases with
an adjustment for days alive and out-of-hospital (99.4 %).
All HF-related hospital episodes were multiplied by the
average cost of hospital stay ($1806 per day).
Future burden
The estimated future trend and growth rate in incidence
and prevalence of HF (once again predominantly that
associated with HFrEF) was projected to 2030 using the
latest population projection data (released in 2013) that
included a moderate assumption on future fertility and
mortality rates and a constant net migration [11]. Con-
servatively, we assumed that the incident and prevalent
cases of HF would remain stable from 2014 to 2030
and the same occurrence statistics were applied to an
increasingly ageing Australian population to form the
projection data.
Table 1 Datasets – purpose and references
Datasets Purpose Reference
Population profile
- Australian Demographics Statistics 2014 To obtain data representating the Australian population
by sex and age as calculated on 30 June 2014
ABS [10]
Incident cases
- Incidence and aetiology of heart failure; a
population-based study
To determine the population incidence of heart failure
data by sex and age groups
Cowie et al. [15]
- Quantifying the heart failure epidemic: prevalence,
incidence rate, lifetime risk and prognosis of heart
failure: The Rotterdam Study
Bleumink et al. [16]
Prevalent cases
- Congestive heart failure in the community a study of all
incident cases in Olmsted County, Minnesota in 1991
To determine the population prevalence of heart failure
data by sex and age groups
Senni et al. [17]
- Prevalence of heart failure and systolic ventricular
dysfunction in older Australians: the Canberra Heart
Study
Abhayaratna et al. [8]
- Quantifying the heart failure epidemic: prevalence,
incidence rate, lifetime risk and prognosis of HF:
The Rotterdam Study
Bleumink et al. [16]
Hospital activity
- Heart Failure Incidence, Case Fatality, and Hospitalisation
Rates in Western Australia Between 1990 and 2005
To evaluate the hospital burden of heart failure Teng et al. [9]
Cost and burden of HF
- Pressure points in primary care: blood pressure and
management of hypertension in 532,050 patients from
2005 to 2010
To investigate the primary care burden of heart failure Carrington et al. [4]
- Impact of Home Versus Clinic-Based Management of
Chronic Heart failure The WHICH? Multicenter,
Randomized Trial
To calculate the financial burden of heart failure Stewart et al. [18]
Future projection
- Population Projections, Australia, 2012 (base) to 2101 To calculate the projection data to 2030 ABS [11]
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Population prevalence of HFpEF
In order to estimate the additional contribution of those
individuals with HFpEF alone (with clear expectations of
older, more female cases with a history of hypertension),
we applied international HFpEF prevalence statistics [17]
according to age and sex, to the Australian population
by 10-year age groups to calculate the point prevalence
of HFpEF as at June 2014.
Results
Incident cases
Annually, we estimate that over 61,000 (or 6.9 per 1000
person-years) Australians aged ≥ 45 years (58 % women)
are diagnosed with HF (Fig. 1). The incidence rate is higher
in men (0.3 per 1000 person-years) aged 45 to 54 years
when compared to women of the same age range (0.1 per
1000 person-years), with a relatively similar upward pattern
for both sexes aged 55 to 74 years. However, in the older
groups, the incidence rate increases exponentially in both
men and women. Greater female longevity translates
into women have higher incidence rates (29.2 per 1000
person-years) in those aged ≥ 75 years (Table 2).
Prevalent cases
Overall, we estimated that, on an annual basis, approxi-
mately 480,000 Australians (66 % men) are affected by
HF predominantly associated with HFrEF. This equates
to 6.3 % (95 % CI 2.6 to 10.0 %) of those aged ≥ 45 years
or 2.1 % (2.8 % of men and 1.4 % of women) of the en-
tire Australian population of 22 million people in 2014.
As anticipated, Fig. 1 shows that most cases were from
the most populous States on the Eastern seaboard of
Australia. New South Wales and the Northern Territory
had the highest and lowest number of people affected by
HFrEF overall with 158,593 (33 %) and 3118 (0.7 %) cases,
respectively. Reflective of global patterns and the clinical
paradigm of HF, the prevalence estimates are five times
higher in men (77,171, 5.1 %) than in women (15,428,
1 %) aged 45 to 54 years and remain higher at each age-
group from 55 to 74 years. However, there is a sharp
increase in prevalent cases of HF in women aged ≥ 75 years
(Table 2).
Hospital activity
There were an estimated 27,468 (45 % of all incident
cases) new HF-related incident admissions in 2014, of
which 60 % were admitted with a primary diagnosis of HF.
Incident admissions increase steeply with advancing age,
especially as a primary diagnosis in those aged ≥ 65 years.
More than 80 % of all incident HF-related admissions
were ‘unplanned’ and the total annual LOS associated with
these admissions was approximately 225,000 days (average
8 days per admission). The majority of those who survive
the index-event return to their own home post-discharge
(79 %) and the remainder (increasing with age) receive
ongoing management via another acute care facility or,
due to general health deterioration, require ongoing resi-
dential care and support (21 %). This latter (and costly)
phenomenon becomes increasingly more likely with each
repetitive hospital admission.
The total number of readmissions within the 12-months
following an incident hospitalisation for HF (of any
Fig. 1 Incident and prevalent cases of heart failure with reduced ejection fraction (HFrEF) in the Australian population according to State and Territory
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diagnosis) is estimated to be > 10,000 separations (37 %
of all incident HF-related admissions). Reflective of an
increasing clinical complexity, often with multimorbid-
ity for those with the syndrome, the risk of readmission
increases steeply with age especially among men aged
up to 75 years (750 separations per 5-year age group)
and women aged ≥ 85 years (1800 separations).
Overall, we estimated that HF contributes to > 147,000
hospital admissions (rate of 166.2 per 10,000 population).
This comprises 45,000 separations (50.6 per 10,000 popu-
lation) as a primary diagnosis and 102,000 separations
(115.6 per 10,000 population) as a secondary diagnosis.
This results in > 1 million days in hospital each year. Of
these, the greatest burden of this debilitating condition is
in hospital stay among persons aged ≥ 65 years (58 % or
587,952 days with a mean LOS of 7.5 days) compared to
those aged < 65 years (42 % or 418,161 days with a mean
LOS of 6.1 days; Table 2).
Costs
Based on the number of prevalent cases of HF (pre-
dominantly those with HFrEF), we estimated that the
annual community management cost is approximately
$867 million and nearly $2.68 billion per annum ($1.46
billion for men versus $1.22 billion for women) when
considering the additional cost of in-patient care ($1.82
billion or 68 % of total expenditure) associated with all
HF-related hospital admissions. Overall, the cost of in-
patient care is twice as high as community care, and in
women only the ratio is three times as high (Fig. 2)
with readmissions constituting a substantial proportion
of all hospitalisation costs.
Table 2 Australian adult population (aged ≥ 45 years) and estimated incident and prevalent cases of heart failure with reduced
ejection fraction (HFrEF) and all hospital activity associated with a primary or secondary composite diagnosis of heart failure
Age (years) Population Incident casesa Prevalent cases Hospital admissionsb (primary/secondary) LOSg (days)
Men
45–54 1,513,403 454 (0.3)c 77,171 (5.1 %)e 18,732 (123.8)g 114,298
55–64 1,283,890 2,831 (2.2)d 94,992 (7.4 %)e 15,747 (122.7)g 95,191
65–74 879,090 7,085 (8.1)d 56,376 (6.4 %)f 16,802 (191.1)g 113,030
75+ 606,842 16,498 (27.2)d 86,488 (14.3 %)f 21,363 (352.0)g 168,600
Total 4,283,225 26,867 (6.3) 315,027 (7.4 %) 72,644 (169.6) 491,119
Women
45–54 1,543,002 154 (0.1)c 15,428 (1.0 %)e 18,680 (121.1)g 113,985
55–64 1,306,222 2,876 (2.2)d 28,734 (2.2 %)e 15,655 (119.8)g 94,687
65–74 899,957 7,281 (8.1)d 28,760 (3.2 %)f 14,783 (164.3)g 99,466
75+ 832,122 24,268 (29.2)d 88,433 (10.6 %)f 25,576 (307.4)g 206,856
Total 4,581,303 34,580 (7.5) 161,355 (3.5 %) 74,703 (163.1) 514,994
LOS length of stay
aCases per 1,000 person-year in the parentheses; badmissions rate per 10,000 person-year in the parentheses; primary or secondary composite diagnosis of heart failure
Key statistics used for estimation cCowie et al., dBleumink et al., eSenni et al., fAbhayaratna et al., gTeng et al.
Fig. 2 Estimated current direct health care cost of clinically overt heart failure according to sex and type of care
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Future burden
Based on a conservative assumption that incident and
prevalent cases of HF (once again predominantly that
relating to HFrEF) would remain stable from 2014 to
2030, we predict that the annual number of HF-related
incident admissions will continue to rise to nearly 35,000
(in 2020) and to more than 47,000 by 2030 (Fig. 3). As ex-
pected, the projected increase in incident admissions in
persons aged ≥ 75 years is significantly greater than in
those aged ≤ 65 years (89 % versus 31 %). Consequently,
a Incident heart failure-related admission
b Prevalent cases of heart failure with reduced ejection fraction (HFrEF) 
Fig. 3 Current and projected estimations of a incident heart failure-related admissions and b overall prevalent cases of heart failure with reduced
ejection fraction (HFrEF) from 2014 to 2030 according to sex and age categories
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we estimate that by 2020, there will be a minimum
prevalent population of approximately 580,000 cases of
HF (an increase of 21 % in men and 25 % in women)
and as many as 750,000 Australians will be affected by
this debilitating syndrome in 2030 (an increase in preva-
lence of 51 % in men and 65 % in women from 2014).
Taken together, this represents a significant increase in an
ageing and rapidly expanding Australian population even
without any changes to incidence or survival rates. We
also predict that the prevalence gap between men and
women will continue and perhaps widen over time, poten-
tially due to the increase in the number of older women
affected by the syndrome.
Additional population prevalence of HFpEF
We estimated that an additional 496,000 Australians (67 %
women) aged ≥ 45 years (6.6 %, 95 % CI 2.1 % to 11.1 %)
are affected by HFpEF alone each year. In contrast to the
age and sex distribution of HFrEF, more women (331,670)
than men (164,182) were likely to be affected by HFpEF.
With the exception of those in the younger age group
(45 to 54 years) where there were three times more
men (54,331) than women (15,893), there were signifi-
cantly more women than men with HFpEF in successively
older age groups (Fig. 4).
Discussion
Despite wide recognition of an evolving burden of HF glo-
bally, there is a lack of high-quality clinical/epidemiological
data to quantify the number of Australians affected by this
deadly syndrome. Using contemporary population data
and conservative estimates derived from robust Australian
and international studies, we estimate that approximately
61,000 new cases of clinically overt HF are diagnosed
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Fig. 4 Prevalent cases of heart failure associated with a reduced ejection fraction (HFrEF) and b preserved ejection fraction (HFpEF) in Australians
aged≥ 45 years according to age categories
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yearly, with a prevalence approaching 480,000 and around
150,000 hospital admissions associated this syndrome
overall. Collectively, patients with a composite diagnosis
(either as primary or secondary) of HF probably contrib-
ute to over 1 million days in hospital at a cost of more
than $2.6 billion (largely due to recurrent hospital care/
episodes). We also predict that, without a substantial
change in the drivers of the syndrome, prevalence of
HF predominantly associated with HFrEF will continue
to grow over the next 10–15 years to nearly 750,000
people with an annual managing cost in excess of $3.8 bil-
lion by 2030. These figures do not reflect the likely add-
itional burden (predominantly affecting older women with
non-ischaemic aetiology) of close to 500,000 Australians
with HFpEF alone. This latter component of the HF bur-
den remains most challenging both in terms of diagnosis
and treatment [19]. However, it cannot be ignored given
the ageing Australian population, even if, as some would
argue, it represents a more benign condition within the
spectrum of the HF syndrome [20].
Comparison between current and previous estimates
Since our first report on the ‘hidden epidemic of HF’ pub-
lished 11 years ago [2], there has been a steady decrease in
coronary artery disease mortality [21] potentially due to
improved medical and therapeutic management. Although
the risk of experiencing a further cardiac event is not
universal and varies considerably across the spectrum
of survivors, it seems probable that the success in treat-
ing these cardiac conditions will increase HF prevalence
now that these patients survive and live longer with
multimorbidity [22]. Our prior estimates of around 325,000
Australians living with HF, 22,000 new HF cases diag-
nosed and 100,000 HF-related hospitalisations in 2000
[2] is in synergy with the current estimates of 480,000
Australians with HF, 27,000 incident HF-related admis-
sions and 147,000 hospitalisations overall, an increase
of 47 %, 23 % and 47 %, respectively, from over a decade
ago. As such, the current estimates support our prior
conclusion of a ‘HF epidemic’ in Australia and demon-
strate an upward trend over time with no sign of slow-
ing down. These data are at odds with official estimates
of around 280,000 HF cases in Australia (population
prevalence 1.3 %). However, such data are almost a dec-
ade old and critically flawed by the fact that they were
derived by a self-reported diagnosis of HF and/or pres-
ence of peripheral oedema [23]. In addition, we found a
higher prevalence of HF specifically related to HFrEF in
men than in women and an exponential trajectory in the
older age groups illustrating the key influence of progres-
sive population ageing. Our data are also consistent with
European, North American and Asian studies [13, 24, 25]
in exploring the size of the HF burden and its consequent
health and economic impacts due to high readmission
rates and long durations of hospital stay, particularly in
the very elderly. However, focussing on HFrEF cases alone
belies the substantive contribution of HFpEF to the current
and future burden of HF in Australia and beyond; particu-
larly when one considers that most clinical studies would
suggest HF predominantly affects men but epidemiological
studies suggest a more even gender balance [26].
Public health implications
HF has become a burgeoning public health problem reach-
ing epidemic levels especially for the older age population.
Currently, our estimate of half a million Australians living
with HF predominantly associated with HFrEF costs the
Australian health care system billions of dollars every year
as well as the broader economic/societal impact on our
community, family and on an individual’s quality of life.
Despite this, HF remains a poorly recognised and under-
appreciated burden in Australia, and the Australian health
care system remains ill-prepared to detect, prevent and
manage this disabling and costly syndrome; particularly in
delineating between cases of HFrEF and HFpEF and diag-
nosing the latter in older women (see below). Our projec-
tions demonstrate a pronounced increase in clinically
overt HF cases especially for the older populations in the
coming decades coupled with escalating social, health and
economic implications if no changes are made.
At the same time, the definition of HFpEF has evolved
and is increasingly recognised as a significant public health
problem worldwide [20, 27]. However, due to the lack of
Australian-specific data and potential disparities in stan-
dardised HFpEF diagnosis between different studies [5],
an accurate assessment is difficult to make compared with
equivalent HFrEF estimations. Individuals with HFpEF
tend to be older at the time of initial diagnosis and
most have a history of hypertension and/or atrial fibril-
lation [26, 28]. In regards to frequency in the popula-
tion, we believe that HFpEF may be as prevalent as
HFrEF and we estimate that women outnumber men by
a 2:1 ratio and its overall prevalence among all persons with
HF (HFrEF and HFpEF) was 43 % in those aged < 65 years
and 56 % in those aged ≥ 65 years. Hence, it is likely that
the overall mortality rate attributable to HFpEF is higher
than HFrEF given the higher proportion of HFpEF in the
older population.
Despite many efforts in improving quality of life and
survival, HF has a poor prognosis with 12 % mortality
within 30 days following an incident admission and cu-
mulative mortality of approximately 31 % and 50 % at
1-year and 5-years, respectively. This is worse than the
prognosis for most cancers [29]. It is prudent that there
is an increasing focus on HF prevention rather than
spending more money on expensive and less effective
treatments for the syndrome. For high-risk individuals
including those with hypertension, diabetes, chronic kidney
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disease, coronary artery disease and vascular disease,
renewed efforts to prevent progressive cardiac dysfunc-
tion should be the focus of research efforts and preventa-
tive health care programs. In addition, the application and
optimisation of proven strategies for HF management
such as ‘gold-standard’ therapeutics [30], devices [31],
tele-monitoring [32] and nurse-led multidisciplinary pro-
grams of care [33] can cost-effectively improve outcomes
in HF. More efforts are also needed to gain better insight
into the drivers of HF hospitalisations (often costly and
prolonged) and preventable (repeated) readmissions that
are imperative for improving individual care and address-
ing broader economic resource implications.
Limitations
A number of specific limitations need to be reinforced in
relation to the estimates derived from this study. Firstly,
there is still a paucity of local data to accurately quantify
the incident to prevalent cases of HF in Australia. There-
fore, large-scale, population-based studies are required to
ascertain the true burden of HF from a number of perspec-
tives including health care utilisation, economic (direct and
indirect) costs and it’s broader societal impact. Secondly,
increasing disease awareness (including the introduction of
broad screening programs), and the continuous rise in the
ageing population will increase the annual incidence of HF.
Thus, future projections must be interpreted with some
caution, given that certain factors may negatively or posi-
tively affect HF incidence and survival rates (fundamental
drivers of prevalence). After careful consideration we have
not included formal sensitivity analyses (over and above
providing confidence intervals for key estimates and
considering key population variables in deriving future
projections of HF) as per original report given the greater
availability of Australian-specific data and our consideration
of the additional burden imposed by HFpEF. Thirdly, the
current impact of antecedents and comorbidities of HF
including coronary heart disease and hypertension and
the prevalence of cardiovascular disease risk factors such
as diabetes, tobacco smoking, excess alcohol, obesity and
physical inactivity will remain influential. These may also
change over time owing to increasing prevalence or im-
proved therapies and management. Consequently, our
projections may potentially under- or over-estimate preva-
lence, depending on the factors considered. Finally, other
confounding factors such as socioeconomic status, access
to primary health and acute care services, admission
thresholds for HF and climatic factors are also likely to
impact on the precise estimation/prediction of the magni-
tude and implications of the HF burden.
Conclusions
In summary, our report uses the latest national and inter-
national clinical and epidemiological data to generate a
contemporary snapshot of the current and potential future
impact of clinically overt HF in Australia. They support
the expectation that HF will continue to impose a sig-
nificant burden both locally and globally in the coming
decades. Without a dramatic change, older and sicker
Australians will develop this deadly and disabling syn-
drome. In response, we need clear preventative strategies
to target the antecedent risk factors and broader determi-
nants to address the complex causes of HF. In addition,
we need more systematic applications that integrate cost-
effective management and treatment. HF, whether it be
described within the confines of HFrEF or broadened to
include cases of HFpEF is an enormous detrimental public
health problem now and for the foreseeable future.
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